Therapy for lowering lipoprotein (a) levels

Current Opinion in Lipidology

Volumn 8, Issue 6, 1997, Pages 337-341

  Angelin, Bo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; ESTROGEN; GEMFIBROZIL; GESTAGEN; GROWTH HORMONE; LIPOPROTEIN A; NICOTINIC ACID; SEX HORMONE; SIMVASTATIN; SOMATOMEDIN C; STATIN;

APHERESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; FEMALE; GENETIC REGULATION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0030786760     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199712000-00003     Document Type: Review

References (60)

1. Wade DP: Lipoprotein (a). Curr Opin Lipidol 1993, 4:244-249.
2. Gaw A, Hobbs HH: Molecular genetics of lipoprotein (a): new pieces to the puzzle. Curr Opin Lipidol 1994, 5:149-155.
3. Berglund U: Diet and drug therapy for lipoprotein (a). Curr Opin Lipidol 1995, 6:48-56.
4. White AL, Lanford RE: Biosynthesis and metabolism of lipoprotein (a). Curr Opin Lipidol 1995, 6:75-80.
5. Marcovina SM, Morrisett JD: Structure and metabolism of lipoprotein (a). Curr Opin Lipidol 1995, 6:136-145.
6. Klezovitch O, Scanu AM: Heterogeneity of lipoprotein (a): growing complexities. Curr Opin Lipidol 1995, 6:223-228.
7. Maher VMG, Brown BG: Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol 1995, 6:229-235.
8. Rosenson RS: Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 1996, 156:1278-1284.
9. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H: Lipoprotein (a) in health and disease. Crit Rev Clin Lab Sci 1996, 33:495-543. An extensive update (containing 238 references), with useful discussions of potential pitfalls in the interpretation of clinical data.
10. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Castelli WP: Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996, 276:544-548.
11. Sechi LA, Kronenberg F, De Carli S, Falleti E, Zingaro L, Catena C, Utermann G, Bartoli E: Association of serum lipoprotein (a) levels and apolipoprotein (a) size polymorphism with target-organ damage in arterial hypertension. JAMA 1997, 277:1689-1695.
12. Grouse JR III: New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis 1996, 7:321-326. A recent evaluation of the clinical usefulness of nicotinic acid treatment.
13. Carlsson LA, Hamsten A, Asplund A: Pronounced lowering of serum lipid levels of lipoprotein (a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 1989, 226:271-276.
14. Seed M, O'Connor B, Knight BL: The effect of nicotinic acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis 1993, 101:61-68.
15. Suefuji H, Ogawa H, Yasue H, Imoto N, Sakamoto T, Miyao Y, Kaikita K, Soejima H, Nishiyama K: Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease. Coron Artery Dis 1996, 7:167-172.
16. Teramoto T, Yamada N, Shimano H, Oka Y, Itakura H, Saito Y, Morisaki N, Shirai K, Ishikawa T, Tada N et al.: Dose-dependent effect of niceritrol on plasma lipoprotein-a. Scand J Clin Lab Invest 1996, 56:359-365.
17. Tanaka K, Hayashi K, Shingu T, Kuga Y, Okura Y, Yasunobu Y, Ohtani H, Nomura S, Kurushima H, Saeki M et al.: Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein (a) levels. Metabolism 1997, 46:355-358.
18. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995, 15:678-682.
19. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996, 275:128-133
20. Bröijersén A, Eriksson M, Angelin B, Hjelmdahl P: Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995, 15:121-127.
21. Jones PH, Pownall HJ, Patsch W, Herd JA, Farmer JA, Payton-Ross C, Kimball KT, Gotto AM, Morrisett JD: Effect of gemfibrozil on levels of lipoprotein (a) in type II hyperlipoproteinemic subjects. J Lipid Res 1996, 37:1298-1308.
22. Belchetz PE: Hormonal therapy of postmenopausal women. N Engl J Med 1994, 330:1062-1071.
23. Kim CJ, Ryu WS, Kwak JW, Park CT, Ryoo UH: Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med 1996, 156:500-504.
24. Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E: Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study. Arch Intern Med 1996, 156:866-872.
25. Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH: Effect of hormone replacement therapy on lipoprotein (a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch Intern Med 1996, 156:1693-1700.
26. Farish E, Spowart K, Barnes JF, Fletcher CD, Calder A, Brown A, Hart DM: Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein (a) and LDL subfractions. Atherosclerosis1996, 126:77-84.
27. Haines CJ, Chung TK, Masarei JR, Tomlinson B, Lau JT: An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein (a) and other lipoproteins. Atherosclerosis 1996, 119:215-222.
28. Taskinen MR, Puolakka J, Pyöräla T, Luotola H, Björn M, Kääriäinen J, Lahdenperä S, Ehnnolm C: Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimes. Arterioscler Thromb Vasc Biol 1996, 16:1215-1221. A carefully executed study showing reductions in Lp(a) levels during treatment both with transdermal oestrogen combined with cyclic progestin (-16%) and with continuous oral oestrogen-progestin (-31%).
29. Henriksson P, Angelin B, Berglund L: Hormonal regulation of serum Lp(a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992, 89:1166-1171.
30. Berglund L, Carlström K, Stege R, Gottlieb C, Eriksson M, Angelin B, Henriksson P: Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996, 81:2633-2637. In spite of drastic changes in hormone levels, no change in Lp(a) was observed in response to parenteral oestrogen; however, a reduction of LDL (-15%) and an increase in HDL-cholesterol (+ 20%) occurred.
31. Denti L, Pasolini G, Cortellini P, Ferretti S, Sanfelici L, Ablondi F, Valenti G: Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein (a). Clin Chem 1996, 42:1176-1181.
32. Arrer E, Jungwirth A, Mack D, Frick J, Patsch W: Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein (a). J Clin Endocrinol Metab 1996, 81:2508-2511.
33. Ozata M, Yildirimkaya M, Bulur M, Yilmaz K, Bolu E, Corakci A, Gundogan MA: Effects of gonadotropin and testosterone treatments on lipoprotein (a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 1996, 81:3372-3378.
34. Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ: Testosterone-induced suppression of lipoprotein (a) in normal men: relation to basal lipoprotein (a) level. Atherosclerosis 1996, 122:89-95.
35. Zmunda JM, Thompson PD, Dickenson R, Bauserman LL: Testosterone decreases lipoprotein (a) in men. Am J Cardiol 1996, 77:1244-1247.
36. Teruel JL, Lasuncion MA, Rivera M, Aguilera A, Ortega H, Tato A, Marcen R, Ortuno J: Nandrolone decanoate reduces serum lipoprotein (a) concentrations in hemodialysis patients. Am J Kidney Dis 1997, 29:569-575.
37. Stenvinkel P, Berglund L: Lipoprotein (a) in chronic renal disease. Miner Electrolyte Metab 1996, 22:16-21.
38. Angelin B, Rudling M: Growth hormone and hepatic lipoprotein metabolism. Curr Opin Lipidol 1994, 5:160-165.
39. Edén S, Wiklund O, Oscarsson J, Rosén T, Bengtsson B-Å: Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993, 13:296-301.
40. Olivecrona H, Ericsson S, Berglund L, Angelin B: Increased concentrations of serum lipoprotein (a) in response to growth hormone treatment. BMJ 1993, 306:1726-1727.
41. Johannsson G, Oscarsson J, Rosen T, Wiklund O, Olsson G, Wilhelmsen L, Bengtsson B: Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and apo(a) and apoE phenotypes. Arterioscler Thromb Vasc Biol 1995, 15:2142-2150.
42. O'Halloran DJ, Wieringa G, Tsatsoulis A, Shalet SM: Increased serum lipoprotein (a) concentrations after growth hormone (GH) treatment in patients with isolated GH deficiency. Ann Clin Biochem 1996, 33:330-334.
43. Garry P, Collins P, Devlin JG: An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. Eur J Endocrinol 1996, 134:61-66.
44. Laron Z, Wang XL, Klinger B, Silbergeld A, Davidovits M, Eisenstein B, Wilcken DE: Growth hormone treatment increases circulating lipoprotein (a) in children with chronic renal failure. J Pediatr Endocrinol Metab 1996, 9:533-537.
45. Tonstad S, Sundt E, Ose L, Hagve TA, Fruchart JC, Bard JM, Edén S: The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein (a) levels in familial hypercholesterolemia. Metabolism 1996, 45:1415-1421.
46. Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L, Angelin B: Hormonal regulation of serum lipoprotein (a) levels: contrasting effects of growth hormone and insulin-like growth factor-I. Artenoscler Thromb Vasc Biol 1995, 15:847-849.
47. Oscarsson J, Lundstam U, Gustafsson B, Wilton P, Edén S, Wiklund O: Recombinant human insulin like growth factor-I decreases serum lipoprotein (a) concentrations in normal adult man. Clin Endocrinol 1995, 42:673-676.
48. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE: Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome. Metabolism 1996, 45:1263-1266.
49. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE: Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein (a). Eur J Endocrinol 1997, 136:377-381.
50. Le Roith D: Insulin-like growth factors. N Engl J Med 1997, 336:633-640.
51. Gordon BR, Saal SD: Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia. Curr Opin Lipidol 1996, 7:381-384.
52. Pokrovsky SN, Sussekov AV, Adamova IY, Afanasieva OI, Benevolenskaya GF, Konovalov GA, Kukharchuk VV: Development of immunosorbents for apoB-containing lipoproteins apheresis. Artific Organs 1995, 19:500-505.
53. Bambauer R, Schiel R, Keller HE, Klinkmann J, Latza R: Low-density lipoprotein apheresis in the treatment of two patients with coronary heart disease and extremely elevated lipoprotein (a) levels. Artific Organs 1996, 20:340-343.
54. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ et al.: Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995, 345:811-816.
55. Kroon AA, Aengevaeren WRM, van der Werf T, Vijen GJH, Reiber JHC, Bruschke AVG, Stalenhoef AFM: LDL Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive vs. conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93:1826-1835. A randomized 2-year study showing similar angiographic changes after LDL apheresis plus simvastatin and after simvastatin treatment only: exercise electrocardiogram changes were reduced after apheresis.
56. Velazquez EM, Mendoza SG, Wang P, Glueck CJ: Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997, 46:454-457
57. Frank S, Durovic S, Kostner K, Kostner GM: Inhibitors for the In vitro assembly of Lp(a). Artenoscler Thromb Vasc Biol 1995, 15:1774-1780.
58. Gavish D, Breslow JL: Lipoprotein (a) reduction by N-acetylcysteine. Lancet 1991, 337:203-204.
59. Kroon AA, Demacker PNM, Stalenhoef AFH: N-acetylcysteine and serum concentration of lipoprotein (a). J Intern Med 1991, 230:519-526.
60. Wiklund O, Fager G, Andersson A, Lundstam U, Masson P, Hultberg B: N-aceytlcysteine treatment lowers plasma homocysteine but not serum lipoprotein (a) levels. Atherosclerosis 1996, 119:99-106.